Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Tvardi Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Tvardi Therapeutics, Inc.’s stock price such as:

• Tvardi Therapeutics, Inc.’s current stock price and volume
• Why Tvardi Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for TVRD from analysts
• TVRD’s stock price momentum as measured by its relative strength

About Tvardi Therapeutics, Inc. (TVRD)

Before we jump into Tvardi Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Want to learn more about Tvardi Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Tvardi Therapeutics, Inc..

Tvardi Therapeutics, Inc.’s Stock Price as of Market Close

As of August 21, 2026, 4:00 PM, CST, Tvardi Therapeutics, Inc.’s stock price was $1.860.

Tvardi Therapeutics, Inc. is up 1.64% from its previous closing price of $1.830.

During the last market session, Tvardi Therapeutics, Inc.’s stock traded between $1.820 and $1.930. Currently, there are approximately 9.38 million shares outstanding for Tvardi Therapeutics, Inc..

Tvardi Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Tvardi Therapeutics, Inc. Stock Price History

Tvardi Therapeutics, Inc.’s (TVRD) price is currently down 11.43% so far this month.

During the month of August, Tvardi Therapeutics, Inc.’s stock price has reached a high of $2.090 and a low of $1.700.

Over the last year, Tvardi Therapeutics, Inc. has hit prices as high as $43.650 and as low as $1.500. Year to date, Tvardi Therapeutics, Inc.’s stock is down 56.74%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Tvardi Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 21, 2026, there were 0 analysts who downgraded Tvardi Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Tvardi Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Tvardi Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Tvardi Therapeutics, Inc. (TVRD) by visiting AAII Stock Evaluator.

Relative Price Strength of Tvardi Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 21, 2026, Tvardi Therapeutics, Inc. has a weighted four-quarter relative price strength of -40.90%, which translates to a Momentum Score of 3 and is considered to be Very Weak.

Want to learn more about how Tvardi Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Tvardi Therapeutics, Inc. Stock Price: Bottom Line

As of August 21, 2026, Tvardi Therapeutics, Inc.’s stock price is $1.860, which is up 1.64% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Tvardi Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.